Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab.
biologic drugs
cohort study
infections
pharmacoepidemiology
population register
psoriasis
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
11
12
2019
revised:
23
07
2020
accepted:
06
09
2020
pubmed:
26
9
2020
medline:
25
11
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
To determine risk of respiratory tract infections, urinary tract infections and candidiasis in secukinumab users compared to ustekinumab users among individuals with psoriasis in Sweden. This was a Swedish population-based register-linked new-user cohort study on individuals with psoriasis and psoriasis arthritis treated with secukinumab (2015-2017) and ustekinumab (2009-2017). Ever-never exposure definition was used, that is, each individual's follow-up time was attributed to the drug they were first exposed to. Risk of severe respiratory and urinary tract infections and candidiasis (diagnosis codes from out-patient specialist visits and in-patient hospitalisations) and respiratory and urinary tract infections treated in primary care (proxied by dispensation of antibiotics) was determined by adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox regression. We also give crude incidence rates and rate ratios. In total, 1955 new users of secukinumab (n = 848) and ustekinumab (n = 1107) were identified. There was a slightly increased risk of respiratory and urinary tract infections treated in primary care among secukinumab users compared to ustekinumab users (HR: 1.22, 95% CI: 1.03-1.43). Non-significant differences in estimated risk of severe respiratory and urinary tract infections (HR: 0.96, 95% CI: 0.57-1.61) and candidiasis (HR: 1.80, 95% CI: 0.84-3.84) treated in the hospital setting were observed. We observed a slightly increased risk of respiratory and urinary tract infections treated in primary care among secukinumab users compared to ustekinumab users. Larger studies with longer follow-up are needed to draw conclusions on relative safety.
Identifiants
pubmed: 32975344
doi: 10.1002/pds.5132
pmc: PMC7756328
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1562-1569Informations de copyright
© 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
Références
Ther Adv Chronic Dis. 2018 Jan;9(1):5-21
pubmed: 29344327
Nat Rev Immunol. 2014 Sep;14(9):585-600
pubmed: 25145755
PLoS One. 2014 May 29;9(5):e98024
pubmed: 24875275
BMC Fam Pract. 2016 Jul 18;17:78
pubmed: 27430895
Nat Rev Rheumatol. 2015 Jul;11(7):437-41
pubmed: 25800216
BMC Infect Dis. 2019 Feb 13;19(1):155
pubmed: 30760219
Indian J Dermatol. 2010 Apr-Jun;55(2):161-70
pubmed: 20606887
Br J Dermatol. 2013 Jun;168(6):1303-10
pubmed: 23374051
Biologics. 2009;3:159-68
pubmed: 19707405
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1124-1130
pubmed: 27365184
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
Clin Ther. 2017 Apr;39(4):675-685
pubmed: 28392076
J Dermatolog Treat. 2018 Sep;29(6):569-578
pubmed: 29532693
Can Fam Physician. 2017 Apr;63(4):278-285
pubmed: 28404701
Pediatr Blood Cancer. 2015 Jul;62(7):1155-61
pubmed: 25790083
Br J Dermatol. 2018 Feb;178(2):509-519
pubmed: 29094341
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1562-1569
pubmed: 32975344
Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579
pubmed: 30334147
J Thromb Haemost. 2016 Apr;14(4):807-14
pubmed: 26792007
Am J Clin Dermatol. 2016 Aug;17(4):329-36
pubmed: 27435194
Br J Dermatol. 2017 Jul;177(1):47-62
pubmed: 27580411
Br J Dermatol. 2017 Oct;177(4):1033-1042
pubmed: 28580579
J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4
pubmed: 27180926
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53
pubmed: 24033851
Indian J Dermatol. 2009;54(2):100-9
pubmed: 20101303
Br J Dermatol. 2013 Apr;168(4):844-54
pubmed: 23301632
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Br J Dermatol. 2017 Dec;177(6):1537-1551
pubmed: 28600810
Int J Dermatol. 1996 Sep;35(9):633-9
pubmed: 8876289
J Am Acad Dermatol. 2015 Sep;73(3):400-9
pubmed: 26092291
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9
pubmed: 27663079
Front Immunol. 2018 Aug 13;9:1668
pubmed: 30150978
Arthritis Res Ther. 2019 May 2;21(1):111
pubmed: 31046809
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii18-23; discussion ii24-5
pubmed: 15708928
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Autoimmun Rev. 2009 Dec;9(2):67-81
pubmed: 19716440